OxThera, a Stockholm, Sweden-based biopharmaceutical company, raised €32m in funding.
The round was co-led by Life Sciences Partners, Ysios Capital, Sunstone Capital, and Flerie Invest, with participation from current shareholders Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden, and Brohuvudet.
The company will use the funds to complete the Oxabact® development program for treatment of Primary hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
Led by Elisabeth Lindner, CEO, OxThera is advancing Oxabact, an oral product composed of concentrated freeze-dried live bacteria (Oxalobacter formigenes), designed for enteric elimination of plasma oxalate. Oxabact holds orphan drug designations in the EU and the US for the treatment of PH, and in EU for treatment of Short Bowel Syndrome (SBS).